Globaltraded.com , Ireland– In a momentous celebration, Aerogen, Ireland’s premier Medtech company, achieved a remarkable milestone by producing its 20 millionth Aerogen Solo, a cutting-edge Aerosol Drug Delivery device revolutionizing respiratory care globally.
Aerogen’s journey, which began in a small room above a butcher’s shop in the West of Ireland, has now spanned 25 years, propelling the company to become a prominent player supporting patients in over 75 countries. The company’s headquarters in Galway, along with manufacturing facilities in Parkmore and Shannon, house a workforce that has tripled in the past five years, totaling 500 employees operating in 28 countries.
The 20 millionth Aerogen Solo, a product globally used by hospital caregivers for acutely compromised respiratory patients, was packaged in a unique gold-branded box, symbolizing the extraordinary achievement. The lucky recipient of this milestone shipment will be acknowledged with a €10,000 donation to the charity of their choice.
Minister Neale Richmond TD, speaking at Aerogen’s milestone event, commended the company’s growth, emphasizing its pivotal role in developing lifesaving respiratory devices for the global health sector. He remarked, “Today’s milestone anniversary is a testament to the talent of all of Aerogen’s staff.”
John Power, Aerogen CEO and Founder, expressed his gratitude and reflected on the impact of the company’s products in treating millions of patients globally. “To be involved in the treatment of 20 million individual patients worldwide is not only a huge privilege but also an incredible honor for us all at Aerogen,” he stated.
As part of its 25th-anniversary celebrations, Aerogen plans a series of 25 events and initiatives to express gratitude to its employees, customers, and communities. The company has already donated over €100,000 to various charities and organizations this year.
Aerogen’s success story is not only reflected in its 25-year journey but also in its financial performance. The parent company, Stamford Devices Limited Group, recorded €119.9 million in revenue for the year ending December 2022. The Medical Device business, with sales of €117 million, resulted in EBITDA of €26.5 million.
The company’s commitment to innovation is evident in its increased investment in Research & Development, reaching €18.5 million in 2022. With a focus on talent management, Aerogen’s success continues to grow, with further investment in people and organic growth reaching 446 direct employees by the end of 2022.
Aerogen’s 20 millionth Solo Aerosol Drug Delivery device stands as a testament to its dedication to excellence in healthcare, and the company looks forward to making a significant impact in the industry for the next 25 years and beyond. (GT)
